Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of 177Lu-DOTATATE for advanced gastroenteropancreatic neuroendocrine tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED